CL2013000423A1 - Forma de dosificacion farmaceutica con resistencia a rompimiento de al menos 500 n, que contiene un ingrediente activo, un polisacarido anionico y un oxido de polialquileno, en donde el ingrediente activo esta presente en una matriz de liberacion controlada comprendiendo el polisacarido anionico y el oxido de polialquileno. - Google Patents
Forma de dosificacion farmaceutica con resistencia a rompimiento de al menos 500 n, que contiene un ingrediente activo, un polisacarido anionico y un oxido de polialquileno, en donde el ingrediente activo esta presente en una matriz de liberacion controlada comprendiendo el polisacarido anionico y el oxido de polialquileno.Info
- Publication number
- CL2013000423A1 CL2013000423A1 CL2013000423A CL2013000423A CL2013000423A1 CL 2013000423 A1 CL2013000423 A1 CL 2013000423A1 CL 2013000423 A CL2013000423 A CL 2013000423A CL 2013000423 A CL2013000423 A CL 2013000423A CL 2013000423 A1 CL2013000423 A1 CL 2013000423A1
- Authority
- CL
- Chile
- Prior art keywords
- active ingredient
- polyalkylene
- oxide
- anionic polysaccharide
- dosage form
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Forma de dosificación farmacéutica con resistencia a rompimiento de al menos 500 n, que contiene un ingrediente activo, un polisacárido aniónico y un óxido de polialquileno, en donde el ingrediente activo está presente en una matriz de liberación controlada comprendiendo el polisacárido aniónico y el óxido de polialquileno.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10009124 | 2010-09-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2013000423A1 true CL2013000423A1 (es) | 2013-04-12 |
Family
ID=43897069
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2013000423A CL2013000423A1 (es) | 2010-09-02 | 2013-02-12 | Forma de dosificacion farmaceutica con resistencia a rompimiento de al menos 500 n, que contiene un ingrediente activo, un polisacarido anionico y un oxido de polialquileno, en donde el ingrediente activo esta presente en una matriz de liberacion controlada comprendiendo el polisacarido anionico y el oxido de polialquileno. |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20120059065A1 (es) |
| EP (1) | EP2611428B1 (es) |
| JP (1) | JP5925778B2 (es) |
| KR (1) | KR20130097201A (es) |
| CN (2) | CN107308124A (es) |
| AR (1) | AR082861A1 (es) |
| AU (1) | AU2011297954B2 (es) |
| BR (1) | BR112013005195A2 (es) |
| CA (1) | CA2808988C (es) |
| CL (1) | CL2013000423A1 (es) |
| CO (1) | CO6670598A2 (es) |
| EC (1) | ECSP13012473A (es) |
| ES (1) | ES2534847T3 (es) |
| HK (1) | HK1184389A1 (es) |
| IL (1) | IL224616A (es) |
| MX (1) | MX340427B (es) |
| NZ (1) | NZ607479A (es) |
| PE (1) | PE20131125A1 (es) |
| PL (1) | PL2611428T3 (es) |
| RU (1) | RU2013114411A (es) |
| TW (1) | TWI501788B (es) |
| WO (1) | WO2012028317A1 (es) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2957281A1 (en) | 2001-09-21 | 2015-12-23 | Egalet Ltd. | Polymer release system |
| EP1429744A1 (en) | 2001-09-21 | 2004-06-23 | Egalet A/S | Morphine polymer release system |
| US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
| EP1610767B1 (en) | 2003-03-26 | 2011-01-19 | Egalet A/S | Morphine controlled release system |
| DE102005005446A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Bruchfeste Darreichungsformen mit retardierter Freisetzung |
| DE102004020220A1 (de) * | 2004-04-22 | 2005-11-10 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform |
| US20070048228A1 (en) | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
| DE102004032051A1 (de) * | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform |
| US8075872B2 (en) | 2003-08-06 | 2011-12-13 | Gruenenthal Gmbh | Abuse-proofed dosage form |
| DE10361596A1 (de) * | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
| DE10336400A1 (de) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
| DE102004032103A1 (de) * | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Gegen Missbrauch gesicherte, orale Darreichungsform |
| DE102004032049A1 (de) * | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Gegen Missbrauch gesicherte, orale Darreichungsform |
| DE102005005449A1 (de) * | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
| DE102007011485A1 (de) * | 2007-03-07 | 2008-09-11 | Grünenthal GmbH | Darreichungsform mit erschwertem Missbrauch |
| AU2008258596B2 (en) | 2007-06-04 | 2013-02-14 | Egalet Ltd | Controlled release pharmaceutical compositions for prolonged effect |
| WO2009092601A1 (en) | 2008-01-25 | 2009-07-30 | Grünenthal GmbH | Pharmaceutical dosage form |
| EP2273983B1 (en) | 2008-05-09 | 2016-07-20 | Grünenthal GmbH | Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step |
| US9005660B2 (en) | 2009-02-06 | 2015-04-14 | Egalet Ltd. | Immediate release composition resistant to abuse by intake of alcohol |
| NZ597283A (en) | 2009-06-24 | 2013-07-26 | Egalet Ltd | Controlled release formulations |
| TW201105316A (en) | 2009-07-22 | 2011-02-16 | Gruenenthal Gmbh | Hot-melt extruded pharmaceutical dosage form |
| AR077420A1 (es) | 2009-07-22 | 2011-08-24 | Gruenenthal Gmbh | Forma de dosificacion resistente a la manipulacion para opiaceos sensibles a la oxidacion |
| CN102821757B (zh) * | 2010-02-03 | 2016-01-20 | 格吕伦塔尔有限公司 | 通过挤出机制备粉末状药物组合物 |
| JP5925779B2 (ja) | 2010-09-02 | 2016-05-25 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 無機塩を含む不正使用抵抗性剤形 |
| PL2611425T3 (pl) | 2010-09-02 | 2014-09-30 | Gruenenthal Gmbh | Odporna na ingerencję postać dawki zawierająca polimer anionowy |
| KR20140053159A (ko) | 2011-07-29 | 2014-05-07 | 그뤼넨탈 게엠베하 | 즉시 약물 방출을 제공하는 탬퍼-저항성 정제 |
| PT2736497T (pt) | 2011-07-29 | 2017-11-30 | Gruenenthal Gmbh | Comprimido resistente a adulteração proporcionando libertação imediata de fármaco |
| AU2013225106B2 (en) | 2012-02-28 | 2017-11-02 | Grunenthal Gmbh | Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer |
| CA2868142A1 (en) | 2012-04-18 | 2013-10-24 | Grunenthal Gmbh | Tamper resistant and dose-dumping resistant pharmaceutical dosage form |
| US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
| US9549899B2 (en) | 2012-07-06 | 2017-01-24 | Egalet Ltd. | Abuse deterrent pharmaceutical compositions for controlled release |
| ES2698611T3 (es) | 2012-07-12 | 2019-02-05 | SpecGx LLC | Composiciones farmacéuticas disuasorias del abuso y de liberación prolongada |
| BR112015026549A2 (pt) | 2013-05-29 | 2017-07-25 | Gruenenthal Gmbh | forma de dosagem à prova de violação contendo uma ou mais partículas |
| JP6466417B2 (ja) | 2013-05-29 | 2019-02-06 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 二峰性放出プロファイルを有する改変防止（ｔａｍｐｅｒ−ｒｅｓｉｓｔａｎｔ）剤形 |
| MX368846B (es) | 2013-07-12 | 2019-10-18 | Gruenenthal Gmbh | Forma de dosificación resistente a la alteración que contiene polímero de acetato de etilen-vinilo. |
| CA3042642A1 (en) * | 2013-08-12 | 2015-02-19 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
| CA2931553C (en) | 2013-11-26 | 2022-01-18 | Grunenthal Gmbh | Preparation of a powdery pharmaceutical composition by means of cryo-milling |
| US10172797B2 (en) | 2013-12-17 | 2019-01-08 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| CN106572980A (zh) | 2014-05-12 | 2017-04-19 | 格吕伦塔尔有限公司 | 包含他喷他多的防篡改即释胶囊制剂 |
| CA2949422A1 (en) | 2014-05-26 | 2015-12-03 | Grunenthal Gmbh | Multiparticles safeguarded against ethanolic dose-dumping |
| CA2955229C (en) | 2014-07-17 | 2020-03-10 | Pharmaceutical Manufacturing Research Services, Inc. | Immediate release abuse deterrent liquid fill dosage form |
| JP2017531026A (ja) | 2014-10-20 | 2017-10-19 | ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド | 徐放性乱用抑止性液体充填剤形 |
| US20160310486A1 (en) | 2015-04-24 | 2016-10-27 | Grünenthal GmbH | Tamper-resistant fixed dose combination providing fast release of two drugs from particles and a matrix |
| CA2983634A1 (en) | 2015-04-24 | 2016-10-27 | Grunenthal Gmbh | Tamper-resistant fixed dose combination providing fast release of two drugs from particles |
| EA035434B1 (ru) | 2015-04-24 | 2020-06-15 | Грюненталь Гмбх | Защищенная от применения не по назначению лекарственная форма с немедленным высвобождением и устойчивостью к экстракции растворителями |
| WO2016170096A1 (en) | 2015-04-24 | 2016-10-27 | Grünenthal GmbH | Tamper-resistant fixed dose combination providing fast release of two drugs from different particles |
| US10183018B2 (en) | 2015-05-28 | 2019-01-22 | Lumosa Therapeutics Co., Ltd. | Pharmaceutical formulations for sustained release of sebacoyl dinalbuphine ester |
| US11234974B2 (en) | 2015-05-28 | 2022-02-01 | Lumosa Therapeutics Co., Ltd. | Pharmaceutical formulations for sustained release of sebacoyl dinalbuphine ester |
| EP3346991A1 (en) | 2015-09-10 | 2018-07-18 | Grünenthal GmbH | Protecting oral overdose with abuse deterrent immediate release formulations |
| WO2017210668A1 (en) * | 2016-06-03 | 2017-12-07 | Jt Pharmaceuticals, Inc. | Sustained release compositions of kappa-opioid receptor agonist |
| US20180028670A1 (en) * | 2016-08-01 | 2018-02-01 | Grünenthal GmbH | Tamper resistant dosage form comprising an anionic polysaccharide |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3612211A1 (de) | 1986-04-11 | 1987-10-15 | Basf Ag | Kontinuierliches verfahren zum tablettieren |
| US5900425A (en) * | 1995-05-02 | 1999-05-04 | Bayer Aktiengesellschaft | Pharmaceutical preparations having controlled release of active compound and processes for their preparation |
| US7141250B2 (en) | 2001-08-06 | 2006-11-28 | Euro-Celtique S.A. | Pharmaceutical formulation containing bittering agent |
| US6471120B1 (en) * | 2001-10-25 | 2002-10-29 | Colgate Palmolive Company | Easy opening handled carton |
| DE10252667A1 (de) | 2002-11-11 | 2004-05-27 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
| EP1610767B1 (en) * | 2003-03-26 | 2011-01-19 | Egalet A/S | Morphine controlled release system |
| DE10336400A1 (de) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
| DE102005005446A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Bruchfeste Darreichungsformen mit retardierter Freisetzung |
| US8075872B2 (en) * | 2003-08-06 | 2011-12-13 | Gruenenthal Gmbh | Abuse-proofed dosage form |
| PL1658054T3 (pl) * | 2003-08-06 | 2007-11-30 | Gruenenthal Gmbh | Postać aplikacyjna zabezpieczona przed nadużyciem |
| DE10361596A1 (de) | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
| DE10360792A1 (de) | 2003-12-23 | 2005-07-28 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
| PL1740156T3 (pl) | 2004-04-22 | 2011-12-30 | Gruenenthal Gmbh | Sposób wytwarzania zabezpieczonej przed nadużyciem, stałej postaci aplikacyjnej |
| BRPI0513300B1 (pt) | 2004-07-01 | 2018-11-06 | Gruenenthal Gmbh | forma farmacêutica oral, protegida frente ao abuso, contendo (1r, 2r)-3-(3-dimetilamino-1-etil-2- metil-lpropil)-fenol |
| CA2572491A1 (en) * | 2004-07-01 | 2006-01-12 | Gruenenthal Gmbh | Oral dosage form safeguarded against abuse |
| PL1765298T3 (pl) | 2004-07-01 | 2013-01-31 | Gruenenthal Gmbh | Sposób wytwarzania stałej postaci dawkowania, która jest zabezpieczona przez nadużywaniem, wykorzystujący wytłaczarkę z przekładnią planetarną |
| DE102005005449A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
| CN101370485A (zh) | 2006-01-21 | 2009-02-18 | 艾博特股份有限两合公司 | 用于滥用药物给药的剂型和方法 |
| DE102007011485A1 (de) | 2007-03-07 | 2008-09-11 | Grünenthal GmbH | Darreichungsform mit erschwertem Missbrauch |
| WO2009092601A1 (en) | 2008-01-25 | 2009-07-30 | Grünenthal GmbH | Pharmaceutical dosage form |
| KR100970665B1 (ko) * | 2008-02-04 | 2010-07-15 | 삼일제약주식회사 | 알푸조신 또는 그의 염을 함유하는 서방성 정제 |
| AU2010206376B2 (en) * | 2009-01-26 | 2012-10-18 | Egalet Ltd. | Controlled release formulations with continuous efficacy |
-
2011
- 2011-09-01 CN CN201710507176.XA patent/CN107308124A/zh active Pending
- 2011-09-01 CA CA2808988A patent/CA2808988C/en not_active Expired - Fee Related
- 2011-09-01 AR ARP110103191A patent/AR082861A1/es unknown
- 2011-09-01 JP JP2013526359A patent/JP5925778B2/ja not_active Expired - Fee Related
- 2011-09-01 WO PCT/EP2011/004404 patent/WO2012028317A1/en active Application Filing
- 2011-09-01 NZ NZ607479A patent/NZ607479A/en not_active IP Right Cessation
- 2011-09-01 CN CN2011800420125A patent/CN103179956A/zh active Pending
- 2011-09-01 ES ES11761000.6T patent/ES2534847T3/es active Active
- 2011-09-01 EP EP11761000.6A patent/EP2611428B1/en not_active Not-in-force
- 2011-09-01 RU RU2013114411/15A patent/RU2013114411A/ru not_active Application Discontinuation
- 2011-09-01 AU AU2011297954A patent/AU2011297954B2/en not_active Ceased
- 2011-09-01 KR KR1020137008511A patent/KR20130097201A/ko not_active Application Discontinuation
- 2011-09-01 PL PL11761000T patent/PL2611428T3/pl unknown
- 2011-09-01 BR BR112013005195A patent/BR112013005195A2/pt not_active IP Right Cessation
- 2011-09-01 US US13/223,358 patent/US20120059065A1/en not_active Abandoned
- 2011-09-01 MX MX2013002120A patent/MX340427B/es active IP Right Grant
- 2011-09-01 PE PE2013000330A patent/PE20131125A1/es active IP Right Grant
- 2011-09-01 TW TW100131418A patent/TWI501788B/zh not_active IP Right Cessation
-
2013
- 2013-02-07 IL IL224616A patent/IL224616A/en active IP Right Grant
- 2013-02-11 CO CO13027448A patent/CO6670598A2/es unknown
- 2013-02-12 CL CL2013000423A patent/CL2013000423A1/es unknown
- 2013-03-01 EC ECSP13012473 patent/ECSP13012473A/es unknown
- 2013-10-24 HK HK13111942.1A patent/HK1184389A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| HK1184389A1 (en) | 2014-01-24 |
| MX2013002120A (es) | 2013-04-03 |
| ECSP13012473A (es) | 2013-04-30 |
| EP2611428B1 (en) | 2015-01-14 |
| WO2012028317A1 (en) | 2012-03-08 |
| EP2611428A1 (en) | 2013-07-10 |
| US20120059065A1 (en) | 2012-03-08 |
| TW201212954A (en) | 2012-04-01 |
| PE20131125A1 (es) | 2013-10-21 |
| PL2611428T3 (pl) | 2015-06-30 |
| CA2808988A1 (en) | 2012-03-08 |
| NZ607479A (en) | 2015-06-26 |
| MX340427B (es) | 2016-07-08 |
| CA2808988C (en) | 2018-05-01 |
| KR20130097201A (ko) | 2013-09-02 |
| IL224616A (en) | 2017-06-29 |
| JP5925778B2 (ja) | 2016-05-25 |
| JP2013536809A (ja) | 2013-09-26 |
| AU2011297954A1 (en) | 2013-03-14 |
| RU2013114411A (ru) | 2014-10-10 |
| CN103179956A (zh) | 2013-06-26 |
| AR082861A1 (es) | 2013-01-16 |
| BR112013005195A2 (pt) | 2016-07-12 |
| ES2534847T3 (es) | 2015-04-29 |
| CN107308124A (zh) | 2017-11-03 |
| TWI501788B (zh) | 2015-10-01 |
| AU2011297954B2 (en) | 2014-05-15 |
| CO6670598A2 (es) | 2013-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2013000423A1 (es) | Forma de dosificacion farmaceutica con resistencia a rompimiento de al menos 500 n, que contiene un ingrediente activo, un polisacarido anionico y un oxido de polialquileno, en donde el ingrediente activo esta presente en una matriz de liberacion controlada comprendiendo el polisacarido anionico y el oxido de polialquileno. | |
| CL2013000424A1 (es) | Forma de dosificacion farmaceutica resistente al rompimiento que comprende a) un ingrediente farmacologicamente activo, b) un polimero, c) un oxido de polialquileno, donde a) esta presente en una matriz de liberacion controlada que comprende b) y c). | |
| CL2013000437A1 (es) | Forma de dosificacion farmaceutica con resistencia a la rotura de al menos 500 n, que contiene un ingrediente activo, 5 al 70 % en peso de una sal inorganica, al menos 30% en peso de un oxido de polialquileno, en donde el ingrediente activo esta integrado en una matriz de liberacion controlada que comprende la sal inorganica y el oxido de polialquileno. | |
| MX2015016254A (es) | Forma de dosificacion resistente al uso indebido con perfil de liberacion bimodal. | |
| EA201400173A1 (ru) | Устойчивая к разрушению таблетка, которая обеспечивает немедленное высвобождение лекарственного средства | |
| CR20140487A (es) | Peliculas de capas multiples capaces de liberar ingredientes activos por un periodo limitado de tiempo | |
| CO6280466A2 (es) | Forma de dosificacion farmaceutica de liberacion controlada | |
| CL2014000904A1 (es) | Forma de dosis farmaceutica oral resistente a la ruptura que comprende i) un ingrediente farmacologicamente activo, ii) un antagonista opioide y/o un agente repelente, iii) un oxido de polialquileno y iv) un polimero anionico. | |
| PE20140255A1 (es) | Tableta dispersable en forma oral | |
| CL2011002968A1 (es) | Forma de dosificacion de extrusion por fusion caliente de un ingrediente activo (a) incluido en una matriz que comprende un polimero (c), que el nucleo presenta una orientacion morfologica ortogonal respecto a la direccion longitudinal de extension de la forma de dosificacion; y su procedimiento de preparacion. | |
| GT201200276A (es) | Combinaciones de compuestos activos | |
| AR087871A1 (es) | Una composicion farmaceutica de rapida disolucion | |
| CL2015002755A1 (es) | Composiciones antibióticas de ceftolozano. | |
| MX348491B (es) | Tableta a prueba de manipulacion que proporciona liberacion inmediata de fármaco. | |
| CL2014001585A1 (es) | Compuestos derivados de betulina; composicion farmaceutica; y el uso de los mismos en el tratamiento y prevencion de una infeccion por vih. | |
| MX2011012929A (es) | Forma de dosificacion resistente a la manipulacion que comprende una matriz y particulas extruidas por fusion que contienen un farmaco. | |
| AR091465A1 (es) | Una composicion farmaceutica que contiene acido nicotinico y/o nicotinamida y/o triptofano para influenciar positivamente la microbiota intestinal | |
| BR112012024432A2 (pt) | composição farmacêutica de dissolução rápida | |
| CL2014003503A1 (es) | Composición farmacéutica para uso intramamario que comprende un ácido fosfónico y al menos un agente antimicrobiano; y uso para el tratamiento o prevención de mastitis en mamífero no humano. | |
| EP3878445A3 (en) | Acamprosate formulations, methods of using the same, and combinations comprising the same | |
| BR112014025041B8 (pt) | Composição farmacêutica | |
| AR086395A1 (es) | Envase para el tratamiento de patologias | |
| AR094289A1 (es) | Sistemas de administracion transdermica de farmacos para levonorgestrel y etinil estradiol | |
| ES2429422R1 (es) | Composición farmacéutica y su uso para preparar un medicamento destinado al tratamiento y la prevención de enfermedades causadas por el VIH | |
| CL2013000762A1 (es) | Composicion que comprende a) una particula de entrega de agente benefico que comprende poli-xiloglucano o poli-galactomanana y b) una mananasa. |